Two-thirds of patients with active inflammatory bowel disease (IBD) at the time of conception will either continue to suffer active symptoms or worsen.1,2 Therefore, we strive to achieve remission in women of childbearing potential before conception. Many of these women will require medications, including biologic agents, to achieve this goal. Anti–tumor necrosis factor (TNF) agents, including infliximab, adalimumab, and golimumab, are immunoglobulin (Ig)G1 monoclonal antibodies, and will be actively transported across the placenta starting in the early second trimester, with 80% of the transfer occurring in the third trimester.